Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$3.15
0.051.61%
At close: -
$3.11
-0.04-1.27%
After Hours: 7:59 PM EDT
Comments
Loading...
Replimune Group Analyst Ratings and Price Targets | NASDAQ:REPL | Benzinga
Replimune Group Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Replimune Group Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
BMO Capital
Barclays
Leerink Partners
JP Morgan
Jefferies
1calculated from analyst ratings
Analyst Ratings for Replimune Group
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
07/23/2025 | — | BMO Capital | $27 → $2 | Downgrade | Outperform → Underperform | |||
07/23/2025 | — | Barclays | $17 → $3 | Downgrade | Overweight → Equal-Weight | |||
07/23/2025 | — | HC Wainwright & Co. | — | Downgrade | Buy → Neutral | |||
07/22/2025 | — | Leerink Partners | $21 → $3 | Downgrade | Outperform → Market Perform | |||
07/22/2025 | — | JP Morgan | $19 → $9 | Downgrade | Overweight → Neutral | |||
07/22/2025 | — | Jefferies | $31 → $6 | Maintains | Buy | |||
07/22/2025 | — | Wedbush | $19 → $4 | Downgrade | Outperform → Neutral | |||
07/16/2025 | — | JP Morgan | $16 → $19 | Maintains | Overweight | |||
07/03/2025 | — | HC Wainwright & Co. | $22 → $22 | Reiterates | Buy → Buy | |||
06/20/2025 | — | Cantor Fitzgerald | — | Initiates | → Overweight | |||
06/02/2025 | — | Piper Sandler | $14 → $22 | Maintains | Overweight | |||
02/26/2025 | — | JP Morgan | $16 → $18 | Maintains | Overweight | |||
02/13/2025 | — | HC Wainwright & Co. | $21 → $22 | Maintains | Buy | |||
01/22/2025 | — | BMO Capital | $18 → $27 | Maintains | Outperform | |||
01/22/2025 | — | HC Wainwright & Co. | $17 → $21 | Maintains | Buy | |||
12/04/2024 | — | Jefferies | $16 → $19 | Maintains | Buy | |||
11/22/2024 | — | BMO Capital | $14 → $18 | Maintains | Outperform | |||
11/22/2024 | — | HC Wainwright & Co. | $17 → $17 | Reiterates | Buy → Buy | |||
11/12/2024 | — | HC Wainwright & Co. | $17 → $17 | Reiterates | Buy → Buy | |||
09/24/2024 | — | JP Morgan | $14 → $17 | Maintains | Overweight | |||
09/16/2024 | — | HC Wainwright & Co. | $17 → $17 | Reiterates | Buy → Buy | |||
09/10/2024 | — | HC Wainwright & Co. | $17 → $17 | Reiterates | Buy → Buy | |||
08/27/2024 | — | Roth MKM | → $17 | Initiates | → Buy | |||
08/13/2024 | — | JP Morgan | $17 → $14 | Maintains | Overweight | |||
06/07/2024 | — | Barclays | $13 → $17 | Maintains | Overweight | |||
06/07/2024 | — | HC Wainwright & Co. | $12 → $17 | Maintains | Buy | |||
12/06/2023 | — | Barclays | $50 → $13 | Maintains | Overweight | |||
11/13/2023 | — | HC Wainwright & Co. | $50 → $48 | Maintains | Buy | |||
11/08/2023 | — | Wedbush | → $52 | Reiterates | Outperform → Outperform | |||
08/07/2023 | — | HC Wainwright & Co. | $51 → $50 | Maintains | Buy | |||
08/01/2023 | — | HC Wainwright & Co. | → $51 | Reiterates | Buy → Buy | |||
06/15/2023 | — | JP Morgan | $38 → $50 | Maintains | Overweight | |||
06/08/2023 | — | HC Wainwright & Co. | → $51 | Reiterates | Buy → Buy | |||
06/07/2023 | — | Wedbush | → $52 | Reiterates | Outperform → Outperform | |||
06/07/2023 | — | EF Hutton | → $60 | Reiterates | Buy → Buy | |||
06/05/2023 | — | HC Wainwright & Co. | $50 → $51 | Maintains | Buy | |||
06/05/2023 | — | EF Hutton | → $60 | Reiterates | Buy → Buy | |||
05/26/2023 | — | EF Hutton | → $60 | Reiterates | Buy → Buy | |||
05/22/2023 | — | Wedbush | → $52 | Reiterates | Outperform → Outperform | |||
04/17/2023 | — | Piper Sandler | → $44 | Assumes | → Overweight | |||
02/10/2023 | — | HC Wainwright & Co. | $48 → $50 | Reiterates | → Buy | |||
01/05/2023 | — | EF Hutton | → $60 | Initiates | → Buy | |||
12/12/2022 | — | BMO Capital | $40 → $70 | Maintains | Outperform | |||
12/07/2022 | — | SVB Leerink | $30 → $34 | Maintains | Outperform | |||
11/04/2022 | — | HC Wainwright & Co. | $60 → $48 | Maintains | Buy | |||
10/14/2022 | — | BMO Capital | $30 → $40 | Maintains | Outperform | |||
10/03/2022 | — | SVB Leerink | $37 → $30 | Maintains | Outperform | |||
08/16/2022 | — | Piper Sandler | $44 → $43 | Maintains | Overweight | |||
08/05/2022 | — | SVB Leerink | $48 → $37 | Maintains | Outperform |
FAQ
What is the target price for Replimune Group (REPL) stock?
The latest price target for Replimune Group (NASDAQ:REPL) was reported by BMO Capital on July 23, 2025. The analyst firm set a price target for $2.00 expecting REPL to fall to within 12 months (a possible -35.69% downside). 24 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Replimune Group (REPL)?
The latest analyst rating for Replimune Group (NASDAQ:REPL) was provided by BMO Capital, and Replimune Group downgraded their underperform rating.
When was the last upgrade for Replimune Group (REPL)?
There is no last upgrade for Replimune Group
When was the last downgrade for Replimune Group (REPL)?
The last downgrade for Replimune Group Inc happened on July 23, 2025 when BMO Capital changed their price target from $27 to $2 for Replimune Group Inc.
When is the next analyst rating going to be posted or updated for Replimune Group (REPL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Replimune Group, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Replimune Group was filed on July 23, 2025 so you should expect the next rating to be made available sometime around July 23, 2026.
Is the Analyst Rating Replimune Group (REPL) correct?
While ratings are subjective and will change, the latest Replimune Group (REPL) rating was a downgraded with a price target of $27.00 to $2.00. The current price Replimune Group (REPL) is trading at is $3.11, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
